Drug
Tunlametinib
Tunlametinib is a pharmaceutical drug with 5 clinical trials. Currently 5 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
5(100%)
Phase Distribution
Ph phase_4
1
20%
Ph phase_3
1
20%
Ph phase_2
3
60%
Phase Distribution
0
Early Stage
3
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
5
trials recruiting
Total Trials
5
all time
Status Distribution
Active(5)
Detailed Status
Recruiting5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 23 (60.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
Trials by Status
recruiting5100%
Recent Activity
5 active trials
Showing 5 of 5
recruitingphase_2
Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
NCT07750067
recruitingphase_4
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
NCT07445022
recruitingphase_2
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
NCT07170293
recruitingphase_2
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
NCT06970353
recruitingphase_3
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
NCT06008106
Clinical Trials (5)
Showing 5 of 5 trials
NCT07750067Phase 2
Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
NCT07445022Phase 4
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
NCT07170293Phase 2
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
NCT06970353Phase 2
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
NCT06008106Phase 3
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5